This article is more than 5 years old. Information may no longer be current.

LADAR6000 gains U.S. marketing approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT WORTH, Texas — An excimer laser with high speed ablation for the treatment of both hyperopia and myopia with and without astigmatism has been granted U.S. regulatory approval, the device’s marketer said in a news release.

Alcon’s LADAR6000 has a “50% faster ablation rate” than previous versions of the LADARVision line, the company said. The Food and Drug Administration also expanded the hyperopic indications for Alcon’s CustomCornea procedures on the LADAR6000 and LADARVision 4000 systems, the company added. In addition to the current range of myopia and myopic astigmatism already approved, the CustomCornea procedure is now approved to treat hyperopia from +0.75 D to +5 D with up to –3 D of cylinder. The LADARVision 4000 is approved to treat myopia up to –7 D with or without astigmatism up to –0.5 D.